FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159794614> ?p ?o ?g. }

• W2159794614 endingPage "168" @default.
• W2159794614 startingPage "159" @default.
• W2159794614 abstract "From July 1983 to January 1991 a total of 622 patients were randomized (585 eligible) to compare the effects of hydroxyurea, interferon alpha (IFN), and busulfan on the duration of chronic phase, and survival. Further goals included the determination of prognostic parameters. 598 CML patients were documented and 575 evaluable. The Ph-status was known for 547 patients. 89.4% of the patients were Ph-positive (+). 11% had additional chromosome aberrations. The median survival of Ph+ patients by now is 4.2 years, that of Ph-patients 1.4 years. Ph-negative patients are older, tend to have lower cell counts and, as a group are more ill at diagnosis. A survival difference of about one year is expected between busulfan and hydroxyurea treated patients. Prospectively evaluated age, organomegaly related symptoms, Karnofsky index, extramedullary manifestations, number of erythroblasts and percent of circulating blasts proved to be of prognostic significance. A prognostic score (score 1) was determined which was superior to Sokal's score in the study population. 164 patients were randomized to receive IFN. In 54 patients (33%) IFN had to be terminated because of adverse effects, therapy resistance or other reasons. Clinically relevant neutralizing antibodies were detected in 9 cases. Most frequent adverse events were flu-like symptoms in 74%, gastrointestinal symptoms in 52%, and neurologic-psychiatric symptoms in 30% of patients. Reduction of the Ph-chromosome was observed in 13% of evaluable patients (10 of 75). In 4 patients complete cytogenetic remissions were observed, in three of these ongoing. Cytogenetic responders have a survival advantage. Interferon treated Philadelphia-negative CML patients have no survival disadvantage. The study is expected to allow statements as to the advantages or disadvantages of the use of busulfan, hydroxyurea and IFN in the treatment of CML as well as to the reliability of prognostic markers." @default.
• W2159794614 created "2016-06-24" @default.
• W2159794614 creator A5002498295 @default.
• W2159794614 creator A5002572636 @default.
• W2159794614 creator A5004907904 @default.
• W2159794614 creator A5006360930 @default.
• W2159794614 creator A5015773961 @default.
• W2159794614 creator A5019397158 @default.
• W2159794614 creator A5021171731 @default.
• W2159794614 creator A5024081046 @default.
• W2159794614 creator A5024927332 @default.
• W2159794614 creator A5025884370 @default.
• W2159794614 creator A5027561867 @default.
• W2159794614 creator A5032925254 @default.
• W2159794614 creator A5033950983 @default.
• W2159794614 creator A5035964802 @default.
• W2159794614 creator A5036871832 @default.
• W2159794614 creator A5044783231 @default.
• W2159794614 creator A5045995079 @default.
• W2159794614 creator A5047335832 @default.
• W2159794614 creator A5051569128 @default.
• W2159794614 creator A5054794845 @default.
• W2159794614 creator A5055871024 @default.
• W2159794614 creator A5056037580 @default.
• W2159794614 creator A5062826516 @default.
• W2159794614 creator A5064114906 @default.
• W2159794614 creator A5067803930 @default.
• W2159794614 creator A5067841095 @default.
• W2159794614 creator A5070364015 @default.
• W2159794614 creator A5071724466 @default.
• W2159794614 creator A5076276301 @default.
• W2159794614 creator A5078417193 @default.
• W2159794614 creator A5079480540 @default.
• W2159794614 creator A5080656211 @default.
• W2159794614 creator A5081068575 @default.
• W2159794614 creator A5086449808 @default.
• W2159794614 creator A5089079739 @default.
• W2159794614 creator A5090985755 @default.
• W2159794614 creator A5091397639 @default.
• W2159794614 creator A5091656568 @default.
• W2159794614 date "1993-01-01" @default.
• W2159794614 modified "2023-10-03" @default.
• W2159794614 title "The German CML Study, Comparison of Busulfan vs. Hydroxyurea vs. Interferon alpha and Establishment of Prognostic Score 1" @default.
• W2159794614 cites W15681308 @default.
• W2159794614 cites W1996173099 @default.
• W2159794614 cites W2000407316 @default.
• W2159794614 cites W2007801084 @default.
• W2159794614 cites W2048956687 @default.
• W2159794614 cites W2054539054 @default.
• W2159794614 cites W2089697181 @default.
• W2159794614 cites W2094674244 @default.
• W2159794614 cites W2269564684 @default.
• W2159794614 cites W2276472705 @default.
• W2159794614 cites W2344147371 @default.
• W2159794614 cites W2471012871 @default.
• W2159794614 cites W2475002365 @default.
• W2159794614 cites W2587781815 @default.
• W2159794614 cites W4242057350 @default.
• W2159794614 cites W4253476700 @default.
• W2159794614 doi "https://doi.org/10.3109/10428199309047880" @default.
• W2159794614 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8251890" @default.
• W2159794614 hasPublicationYear "1993" @default.
• W2159794614 type Work @default.
• W2159794614 sameAs 2159794614 @default.
• W2159794614 citedByCount "13" @default.
• W2159794614 countsByYear W21597946142020 @default.
• W2159794614 crossrefType "journal-article" @default.
• W2159794614 hasAuthorship W2159794614A5002498295 @default.
• W2159794614 hasAuthorship W2159794614A5002572636 @default.
• W2159794614 hasAuthorship W2159794614A5004907904 @default.
• W2159794614 hasAuthorship W2159794614A5006360930 @default.
• W2159794614 hasAuthorship W2159794614A5015773961 @default.
• W2159794614 hasAuthorship W2159794614A5019397158 @default.
• W2159794614 hasAuthorship W2159794614A5021171731 @default.
• W2159794614 hasAuthorship W2159794614A5024081046 @default.
• W2159794614 hasAuthorship W2159794614A5024927332 @default.
• W2159794614 hasAuthorship W2159794614A5025884370 @default.
• W2159794614 hasAuthorship W2159794614A5027561867 @default.
• W2159794614 hasAuthorship W2159794614A5032925254 @default.
• W2159794614 hasAuthorship W2159794614A5033950983 @default.
• W2159794614 hasAuthorship W2159794614A5035964802 @default.
• W2159794614 hasAuthorship W2159794614A5036871832 @default.
• W2159794614 hasAuthorship W2159794614A5044783231 @default.
• W2159794614 hasAuthorship W2159794614A5045995079 @default.
• W2159794614 hasAuthorship W2159794614A5047335832 @default.
• W2159794614 hasAuthorship W2159794614A5051569128 @default.
• W2159794614 hasAuthorship W2159794614A5054794845 @default.
• W2159794614 hasAuthorship W2159794614A5055871024 @default.
• W2159794614 hasAuthorship W2159794614A5056037580 @default.
• W2159794614 hasAuthorship W2159794614A5062826516 @default.
• W2159794614 hasAuthorship W2159794614A5064114906 @default.
• W2159794614 hasAuthorship W2159794614A5067803930 @default.
• W2159794614 hasAuthorship W2159794614A5067841095 @default.
• W2159794614 hasAuthorship W2159794614A5070364015 @default.
• W2159794614 hasAuthorship W2159794614A5071724466 @default.
• W2159794614 hasAuthorship W2159794614A5076276301 @default.
• W2159794614 hasAuthorship W2159794614A5078417193 @default.
• W2159794614 hasAuthorship W2159794614A5079480540 @default.

• next